Q1 2026 · 13F-HR
Nan Fung Group Holdings Ltdholdings as filed
Filed 2026-05-14 · accession 0001012975-26-000423
$121.3M
Reported value
24
Positions
2026-03-31
Period end
The Brief · Nan Fung Group Holdings Ltd · Q1 2026
AI · grounded in 13F
Nan Fung Group Holdings Ltd established a new position in CELC valued at $3.23M. The fund also opened a new position in INSM for $1.08M and increased its stake in LBRX by 110.22%. On the sell side, the fund closed its position in LAB, reducing its exposure by $2.41M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 30054Y107 | EVMN | EVOMMUNE INC | $33.1M | 27.3% | 1,441,032 | Common | SOLE |
| 56565P103 | MPLT | MAPLIGHT THERAPEUTICS INC | $19.7M | 16.3% | 971,253 | Common | SOLE |
| 50180M108 | LBRX | LB PHARMACEUTICALS INC | $15.6M | 12.8% | 630,657 | Common | SOLE |
| H5870P102 | OCS | OCULIS HOLDING AG | $9.3M | 7.69% | 350,745 | Common | SOLE |
| 45337C102 | INCY | INCYTE CORP | $5.1M | 4.17% | 53,742 | Common | SOLE |
| 07725L102 | ONC | BEONE MEDICINES LTD | $4.7M | 3.85% | 15,722 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $4.3M | 3.52% | 49,120 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $3.2M | 2.66% | 28,300 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $3.1M | 2.57% | 13,600 | Common | SOLE |
| 74275K108 | PCOR | PROCORE TECHNOLOGIES INC | $3.0M | 2.51% | 53,299 | Common | SOLE |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS INC | $3.0M | 2.45% | 5,672 | Common | SOLE |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $2.6M | 2.12% | 30,875 | Common | SOLE |
| 004225108 | ACAD | ACADIA PHARMACEUTICALS INC | $2.3M | 1.89% | 102,984 | Common | SOLE |
| 23256X407 | HELP | CYBIN INC | $2.2M | 1.82% | 460,000 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $2.0M | 1.69% | 2,800 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $1.9M | 1.54% | 19,253 | Common | SOLE |
| 75629V104 | RXRX | RECURSION PHARMACEUTICALS IN | $1.8M | 1.51% | 595,287 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $1.1M | 0.89% | 6,580 | Common | SOLE |
| 46438R105 | ETHA | ISHARES ETHEREUM TR | $800,191 | 0.66% | 50,549 | Common | SOLE |
| 413197104 | HRMY | HARMONY BIOSCIENCES HLDGS IN | $757,642 | 0.62% | 27,049 | Common | SOLE |
| 29384C108 | TRDA | ENTRADA THERAPEUTICS INC | $619,415 | 0.51% | 49,082 | Common | SOLE |
| 46438F101 | IBIT | ISHARES BITCOIN TRUST ETF | $613,491 | 0.51% | 15,968 | Common | SOLE |
| 753018100 | RANI | RANI THERAPEUTICS HLDGS INC | $362,686 | 0.30% | 493,584 | Common | SOLE |
| 097702203 | BOLT | BOLT BIOTHERAPEUTICS INC | $118,170 | 0.10% | 29,250 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.